Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q1- Text added to 2022 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
AbbVie, ADC, Akesobio, Anderson, bladder, Boehringer, Center, companion, Conjupro, Connecticut, CTDPA, earthquake, enfortumab, ethnically, exemption, flood, furnish, ImmunceOnco, ImmuneOncia, immunotherapy, impede, indolent, Ingelheim, interval, IST, Lab, lenalidomide, lymphoma, Mabwell, Monkeypox, NHL, ODD, Online, PADCEV, paused, racially, SinoBiological, Sorrento, TG, UC, upcoming, urothelial, VAT, vi, Waterstone, Zai
Removed:
Dr, Hong, India, minimum, partially, Wan
Valuein 2022 Q1 filing- Value in 2022 Q2 filing
Original filings
Filing view